Pneumonia Therapeutics Market Development, Key Opportunity, Application & Forecast to 2026

The global pneumonia therapeutics market is anticipated to observe a significant growth due to increasing incidences of pneumococcal disease and surging government initiatives towards pneumonia treatment. Pneumonia is a severe respiratory disease and it annually affects a significant number of the global population, calling for effective treatment options, which would fuel the industry outlook.

Pneumococcal disease, which is caused due to Streptococcus pneumonia, can severely infect the lungs and causes bacterial meningitis, middle ear infection, and blood infection among others. As per the CDC (Centers for Disease Control and Prevention), pneumococcal pneumonia is responsible for about 150,000 hospitalizations per year solely across the U.S., expediting business progression.

Get sample copy of this research report @

With respect to drug class, the market is bifurcated into antibacterial drugs, antiviral drugs, and antifungal drugs. Of these, the antibacterial drugs segment dominated the industry with a revenue share of more than 60% in 2019. Antibacterial drugs are further classified into macrolides and quinolones. These drugs are commonly used for the treatment of pneumonia that is community-acquired. In addition, macrolides antibiotics like azithromycin, and clarithromycin among others are widely used to protect children from pneumonia, which should further augment the segment share.

In terms of the age group, the pneumonia therapeutics market is characterized by the geriatric, adult, and pediatric groups. Owing to children’s weak and underdeveloped immune systems, they are more vulnerable to pneumonia, which is expected to further push the pediatric age group segment growth.

Through the regional perspective, increasing geriatric population, particularly in the U.S., is expected to push the North America pneumonia therapeutics market over the coming years. In fact, the U.S. pneumonia therapeutics industry is slated to expand at a healthy CAGR of more than 6.3% over the forthcoming timeframe.

Major pharmaceutical companies are increasingly making efforts to discover new treatment options that addresses the disease in a more effective and quick manner. Taking June 2020 for instance, the U.S. FDA approved Recarbrio for the treatment of ventilator-linked bacterial pneumonia and hospital-acquired bacterial pneumonia in patients aged 18 and older. Recarbrio was earlier approved by the FDA to treat patients suffering from complicated intra-abdominal infections and urinary tract infections that have very limited or no other treatment options.

The competitive landscape of the pneumonia therapeutics market is inclusive of players such as GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Sanofi, Novartis, Mylan, Lupin Pharmaceuticals, Cipla, and Bayer among others.

Request for a Customization of this research report @

Partial Chapter of the Table of Content

Chapter 5. Pneumonia Therapeutics Market, By Age Group

5.1. Key segment trends

5.2. Pediatric

5.2.1.  Pediatric market by region, 2015 - 2026 (USD Million)

5.3. Adult

5.3.1.  Adult market, by region, 2015 - 2026, (USD Million)

5.4. Geriatric

5.4.1.  Geriatric market by region, 2015 - 2026 (USD Million)

Chapter 6. Pneumonia Therapeutics Market, By Application

6.1. Key segment trends

6.2. Pediatric

6.2.1. Pediatric pneumonia therapeutics industry, by region, 2015 - 2026, (USD Million)

6.3. Adult

6.3.1. Adult pneumonia therapeutics industry, by region 2015 - 2026, (USD Million)

6.4. Geriatric

6.4.1. Geriatric pneumonia therapeutics industry, by region 2015 - 2026, (USD Million)

6.5. Veterinary

6.5.1. Veterinary pneumonia therapeutics industry, by region 2015 - 2026, (USD Million)

Chapter 7. Pneumonia Therapeutics Market, By Infection Type

7.1. Key segment trends

7.2. Hospital-acquired pneumonia (HAP)

7.2.1.  Hospital-acquired pneumonia (HAP) market, by region, 2015 - 2026, (USD Million)

7.3. Community-acquired pneumonia (CAP)

7.3.1.  Community-acquired pneumonia (CAP) market, by region, 2015 - 2026, (USD Million)

7.4. Ventilator-associated pneumonia (VAP)

7.4.1.  Ventilator-associated pneumonia (VAP) market, by region, 2015 - 2026, (USD Million)

Browse complete Table of Contents (ToC) of this research report @